Protein expression of SEC62 in triple-negative breast cancer

M Kasoha; Z Takacs; J Radosa; R Bohle; G Schmidt; M Linxweiler; B Schick; I Juhasz-Böss; EF Solomayer

doi:10.1055/s-0038-1675454

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2018; 78(11): 1151-1152
DOI: 10.1055/s-0038-1675454

Abstracts

Georg Thieme Verlag KG Stuttgart · New York

Protein expression of SEC62 in triple-negative breast cancer

Authors

M Kasoha

¹Department of Obstetrics, Gynecology and Reproductive Medicine, University of Saarland, Homburg/Saar, Germany
Z Takacs

¹Department of Obstetrics, Gynecology and Reproductive Medicine, University of Saarland, Homburg/Saar, Germany
J Radosa

¹Department of Obstetrics, Gynecology and Reproductive Medicine, University of Saarland, Homburg/Saar, Germany
R Bohle

²Institute for General and Special Pathology, University of Saarland, Homburg/Saar, Germany
G Schmidt

¹Department of Obstetrics, Gynecology and Reproductive Medicine, University of Saarland, Homburg/Saar, Germany
M Linxweiler

³Department of Otorhinolaryngology, University of Saarland, Homburg/Saar, Germany
B Schick

³Department of Otorhinolaryngology, University of Saarland, Homburg/Saar, Germany
I Juhasz-Böss

¹Department of Obstetrics, Gynecology and Reproductive Medicine, University of Saarland, Homburg/Saar, Germany
EF Solomayer

¹Department of Obstetrics, Gynecology and Reproductive Medicine, University of Saarland, Homburg/Saar, Germany

Abstract

Full Text

Background:

Breast cancer (BC) is the most common malignant tumor disease of women worldwide. Approximately 15 – 20% of patients have a specific subtype defined by the lack of expression of the estrogen receptor and progesterone receptor as well as Her2. This subtype is called triple-negative breast carcinoma (TNBC) and is associated with bad outcomes including early metastasis, early relapse, and poor overall survival. Since neither antihormonal- nor a Her2-neu directed antibody therapy is possible, the treatment options in these cases are very limited. Therefore, further prognostic markers are needed to better adapt the treatment strategy to the disease. SEC62, a gene located at chromosomal region 3q26.2 that encodes an endoplasmic reticulum (ER) transmembrane protein, is found to be overexpressed and significantly associated with a worse prognosis in various cancer types such as non-small cell lung cancer, thyroid cancer, and head and neck squamous cell carcinoma. Therefore, we aimed in this study to investigate SEC62 expression in TNBC to evaluate its possible role as a prognostic and predictive biomarker in this tumor entity.

Materials and methods:

60 women with histologic confirmed TNBC were enrolled in this study. Representative formalin-fixed paraffin-embedded tumour blocks of all patients were obtained from the department of pathology of our hospital and 3 tissue microarray blocks were developed. Immunohistochemical staining for SEC62 was performed and staining results were analysed by an experienced pathologist. SEC62 expression was correlated with the clinicopathologic findings and overall survival data.

Results and Conclusion:

These will be showed later in TRAFO.